Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
Bo Xu, Shengxian Tu, Lei Song...
https://pubmed.ncbi.nlm.nih.gov/34742368/Actively Recruiting
Led by China National Center for Cardiovascular Diseases · Updated on 2026-09-24
10000
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are conducting a large, prospective, multicenter observational registry across more than 50 hospitals in China to evaluate coronary revascularization in patients with coronary artery disease. The study focuses on patients who have at least one main branch coronary artery stenosis of 50% or greater, as seen on coronary angiography. It aims to establish a quantitative flow ratio QFR-based quality control standard system to guide coronary revascularization decisions and assess its real-world adoption. Participants include patients with acute coronary syndrome such as unstable angina and certain types of myocardial infarction older than 4 weeks or chronic coronary syndrome including stable angina and silent myocardial ischemia who undergo percutaneous coronary intervention PCI or receive conservative treatment. Coronary angiographic images and intracoronary imaging, when available, will be collected and analyzed retrospectively by an independent core laboratory. Various subgroup analyses will examine concordance rates between clinical decisions and QFR assessments, along with other disease and hospital-related factors. During the study, participants coronary images are submitted for detailed QFR analysis to measure blood flow and guide treatment quality. Researchers will monitor major adverse cardiac events, death, myocardial infarction, target vessel revascularization, any coronary revascularization, and stent thrombosis at 6 months, 1 year, 3 years, and 5 years. The primary measurement is the QFR adoption rate at enrollment. The study will continue through 2029, with ongoing data collection and follow-up to better understand treatment outcomes and quality control in coronary artery disease care.
CONDITIONS
A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation
J
Jie Qian, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
China National Center for Cardiovascular Diseases
Lead Sponsor
Guangdong Provincial People's Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants undergo coronary angiography and their images are collected for analysis. Medical history and treatment details are recorded. Follow-up assessments occur to monitor heart-related events.
Follow-up visits at 6 months, 1 year, 3 years, and 5 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Bo Xu, Shengxian Tu, Lei Song...
https://pubmed.ncbi.nlm.nih.gov/34742368/Rui Zhang, Hao-Yu Wang, Lei Song...
https://pubmed.ncbi.nlm.nih.gov/41263729/Christiaan Vrints, Felicita Andreotti, Konstantinos C Koskinas...
https://pubmed.ncbi.nlm.nih.gov/39210710/Bo Xu, Shengxian Tu, Shubin Qiao...
https://pubmed.ncbi.nlm.nih.gov/29101020/China National Center for Cardiovascular Diseases
Lead Sponsor
Guangdong Provincial People's Hospital
Collaborating Sponsor